Clinical trials: HIV/AIDS
Drug Interaction
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
This study evaluates whether there is an interaction between etonogestrel, the progestin hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication used to treat HIV.
- Trial name
- NCT01980342
- Testing
- Efavirenz
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female…
- Trial name
- NCT00764946
- Testing
- Comparator: raltegravir
- Volunteers
- 209 people
- Sponsor
- Merck Sharp & Dohme LLC
Aids, Cdc Group I
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular immunity against HIV-1. Target group: Untreated healthy individuals with chronic HIV-1 infection.
- Trial name
- HIV-BIS (NCT01141205)
- Testing
- AFO-18, Saline
- Where
- 2 sites in Guinea-Bissau
- Volunteers
- 18 people
- Sponsor
- Statens Serum Institut
HIV, Cardiovascular Disease
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
The purpose of this study is to evaluate the effects of IL-1β inhibition on safety, measures of systemic and vascular inflammation and endothelial function (all indicators of cardiovascular risk) in treated and suppressed HIV…
- Trial name
- NCT02272946
- Testing
- Canakinumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Priscilla Hsue, MD
HIV, Inflammation
Zinc Supplementation and Cardiovascular Risk in HIV
The purpose of this pilot study is to determine whether zinc supplementation significantly affects immune activation in HIV-infected subjects.
- Trial name
- NCT02856269
- Testing
- Zinc gluconate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Grace McComsey
HIV Infections
Improving Treatment and Retention Adherence in Nontraditional Settings
This is a hybrid implementation-effectiveness study using both qualitative and quantitative methods. The research aims to examine whether providing a new, but approved, HIV once a month injection treatment…
- Trial name
- I-TRAINS (NCT04973254)
- Testing
- CAB-RPV LA, Standard treatment within an HIV clinic
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boston Medical Center
HIV Disease
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
The purpose of this study was to compare the use of lamivudine (3TC) or emtricitabine (FTC) alone vs. continuing a failing highly active antiretroviral therapy (HAART) regimen in HIV infected children, adolescents and young…
- Trial name
- P1094 (NCT01338025)
- Testing
- HAART regimen, 3TC or FTC monotherapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 33 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g.
- Trial name
- NCT00876733
- Where
- 66 sites in Germany
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1…
- Trial name
- NCT01309243
- Testing
- FTC/RPV/TDF, EFV/FTC/TDF
- Where
- 151 sites in United States, Australia and 12 more
- Volunteers
- 799 people
- Sponsor
- Gilead Sciences
HIV, HIV Lipodystrophy
Effects of Growth Hormone Releasing Hormone in HIV
HIV-infection and its treatment are often associated with an increase in belly fat, as well as abnormal cholesterol and problems metabolizing sugar.
- Trial name
- NCT01263717
- Testing
- tesamorelin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Massachusetts General Hospital
HIV Infection
Aspirin and Antiretroviral Therapy in HIV Infected Patients
The purpose of this study is to examine the effects of HIV treatment (antiretroviral therapy) and aspirin use on risk for cardiovascular disease among HIV infected persons.
- Trial name
- NCT00783614
- Testing
- Aspirin 325mg, Antiretroviral therapy (ART)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Hennepin Healthcare Research Institute
HIV Prevention
Randomized Controlled Trial of Game Changers
The study is a randomized controlled trial (RCT) of Game Changers, an 8-session peer-led group intervention that aims to empower and mobilize people living with HIV (PLWH) to be agents for HIV prevention in their social networks.
- Trial name
- NCT05098015
- Testing
- Game Changers
- Where
- Uganda
- Volunteers
- 809 people
- Sponsor
- RAND
Human Immunodeficiency Virus
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
Background: The immune system protects the body from infection. But it can also cause harm. For example, the clotting system makes blood clot and protects from bleeding. But blood clots are sometimes harmful.
- Trial name
- NCT02081638
- Testing
- Aspirin, Atorvastatin
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Functional Interval Training for Veterans Exercising Through Telehealth.
Most Veterans living with HIV are 50 years of age or older and can expect to live more than 20 years longer with HIV medication.
- Trial name
- FIT-VET (NCT04103593)
- Testing
- exercise training
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- VA Office of Research and Development
HIV Infection
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a…
- Trial name
- NCT04223778
- Testing
- DOR/ISL, ART
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 672 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
To explore the hypothesis that the use of Lopinavir/ritonavir will be associated with improved CD4 immune reconstitution in volunteers who fail to demonstrate a significant CD4 cell increase (while on their first antiretroviral…
- Trial name
- NCT00344487
- Testing
- Lopinavir/Ritonavir
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Maryland, Baltimore
HIV Infections
New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr.
- Trial name
- NewEra (NCT00908544)
- Testing
- PHI-patients, CHI-patients
- Where
- 8 sites in Germany
- Volunteers
- 47 people
- Sponsor
- MUC Research GmbH
Infection, Human Immunodeficiency Virus
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study.
- Trial name
- NCT02105987
- Testing
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Where
- 103 sites in United States, Canada and 1 more
- Volunteers
- 555 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, Violence
Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa
This study will evaluate the impact of the Common Elements Treatment Approach (CETA), an evidence-based intervention comprised of cognitive-behavioral therapy elements, at improving HIV treatment outcomes among women with HIV who…
- Trial name
- CETA (NCT04242992)
- Testing
- CETA, Short Message Service (SMS) text reminders
- Where
- South Africa
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Boston University
HIV, HIV Pre-exposure Prophylaxis
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1)…
- Trial name
- NCT06045507
- Testing
- MK-8527
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.